On June 18, Hengrui Medicine rose 3.02% in regular trading, trading at 54.7 HKD/share, with turnover of approximately 46.74 million HKD. The rally was driven by a convergence of positive catalysts including new drug approvals, clinical trial advancements, and institutional accumulation.

On the regulatory front, NMPA approved a new indication for Hengrui's dalpiciclib isethionate tablets (a CDK4/6 inhibitor) for early-stage breast cancer with high recurrence risk. Separately, HRS-7525 tablets and SHR-6914 injection both received clinical trial approvals for solid tumors and prostate cancer-related tumors, respectively, further expanding the company's oncology pipeline.

On the capital side, Schroders increased its stake by approximately 948,800 shares on June 12 at around 54.54 HKD per share, lifting its holding from 4.75% to 5.11%. Meanwhile, management continued its A-share buyback program, repurchasing 120,000 shares on June 17 at approximately RMB 46.85–46.88 per share, spending roughly RMB 5.62 million, signaling confidence in the company's intrinsic value.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)